Breathtaking
Achievements.
CellSight is dedicated to advancing and disseminating knowledge that propels us to share our findings openly and transparently. Through our commitment to research and innovation, we strive to contribute to the collective pool of knowledge, foster collaboration, and drive progress in our field.
Publications
[18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy
Levi J. et al.|October 24th, 2024
Journal of Nuclear Medicine, 2024.
Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer
Wijngaarden J. et al.|October 8th, 2024
Res Sq [Preprint]
European Journal of Nuclear Medicine and Molecular Imaging, 2024.
Enrichment of novel CD3+F4/80+ cells in brown adipose tissue following adrenergic stimulation
Chae H. et al.|August 26th, 2024
Frontiers Immunology, 2024.
A feasibility study of [18F]F-AraG positron emission tomography (PET) for cardiac imaging - myocardial viability in ischemia-reperfusion injury model
Shrestha U. et al.|July 26th, 2024
Res Sq [Preprint]
Molecular Imaging and Biology, 2024.
Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection
Peluso M.J. et al.|July 3rd, 2024
Science Translational Medicine, 2024.
[18F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue
Levi J. et al.|July 1st, 2024
Nature Communications Biology, 2024.
Total-Body Dynamic Imaging and Kinetic Modeling of [18F]F-AraG in Healthy Individuals and a Non–Small Cell Lung Cancer Patient Undergoing Anti–PD-1 Immunotherapy
Omidivari N. et al.|September 3rd, 2023
Journal of Nuclear Medicine, 2024.
The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.
Levi J. and Song H.|January 1st, 2023
Frontiers in Immunology, 2023.
Presentations
4th International congress on inflammation and infection imaging 2024 Rome
Levi J.|December 6th, 2024
[18F]F-AraG in monitoring response and predicting outcomes in patients with cancer treated with PD-(L)1 therapy
WMIC 2024 Montréal
Levi J.|September 9th, 2024
[18F]F-AraG uptake in the vertebral bone marrow predicts survival in immunotherapy treated non-small cell lung cancer patients
SNMMI 2024 Toronto
Levi J. |June 10th, 2024
Simultaneous imaging of activated lymphocytes and adipocytes with [18F]F-AraG reveals association between neuroinflammation and brown- and bone marrow adipose tissue
SNMMI 2024 Toronto
Nobashi T.|June 9th, 2024
Psyhological Uptake of 18F-AraG immunoPET in Non-Small Cell Lung Cancer Patients in Japan.
Immunology 2024 Chicago
Chae H-D.|May 5th, 2024
Emergence of novel CD3+ Macrophages in Brown Adipose Tissue Following Adrenergic Stimulation
EMIM 2024 Porto
Guglielmetti C.|March 15th, 2024
18F-AraG PET imaging of activated T cells differentiates between acute and chronic lesions in a multiple sclerosis model
EMIM 2024 Porto
Wijngaarden J.E.|March 15th, 2024
Pharmacokinetic analysis and simplified uptake measures for tumor lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer
EMIM 2024 Porto
Levi J.|March 13th, 2024
18F-AraG Accumulates in Metabolically Active Brown- and Bone Marrow Adipose Tissue
See more section
CROI 2024 Colorado
Henrich T.|March 4th, 2024
[18F]F-AraG PET Imaging Reveals Unique Tissue T Cell Activation Patterns Across HIV Infection States
SNNMI 2023 Chicago
Shrestha U. |January 1st, 2023
A novel mitochondrial-targeted [18F]F-AraG positron emission tomography (PET) biomarker for early diagnosis and monitoring of cardiotoxicity.
iSRS 2023 Hawaii
Blecha J.|January 1st, 2023
Synthesis of [18F]F-AraG Using a Second-Generation Precursor and Its Utility Across Multiple Radiochemistry Platforms.